Japanese Pharma Majors Expanding Into India
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Faced with margin pressures elsewhere, pharmaceutical multinationals have been eyeing the burgeoning Indian market ever since the country signed the Trade-Related Aspects of Intellectual Property Rights pact. Initially hesitant, Japanese pharma companies are now following in the footsteps of Western companies, using India as a hub for low-cost contract manufacturing and clinical trials
You may also be interested in...
Eisai Plans R&D Revamp To Turn The Development Tide
Six autonomous product creation units to focus on neuroscience, oncology, antibodies and immunological anti-inflammatory diseases, with units also focused on late stage drugs and Japanese clinical research.
Eisai Plans R&D Revamp To Turn The Development Tide
Six autonomous product creation units to focus on neuroscience, oncology, antibodies and immunological anti-inflammatory diseases, with units also focused on late stage drugs and Japanese clinical research.
Eisai Plans R&D Structure Revamp, Hoping To Turn The Development Tide
TOKYO - Eisai CEO Haruo Naito unveiled plans to revamp the company's research and development structure in hopes of having his employees produce better results, Naito told analysts Feb. 27 in Tokyo